Background. Although known for its efficacy in
treatment-resistant schizophrenia, the usage of
clozapine has been limited due to concerns over potential adverse effects.
Myocarditis, one potential fatal complication, can develop at any point during treatment but has been most commonly observed 2-3 weeks after
clozapine initiation. Objective. A case of acute
clozapine-induced
myocarditis is described, highlighting the history, onset, and treatment course of presentation. There is a need to raise awareness of this potential complication, especially in the pediatric population. Results. 17-year-old Puerto Rican boy, with history of
schizophrenia, disorganized type (treatment resistant), and
intellectual disability, developed
myocarditis on the thirteenth day following
clozapine commencement. Initial presenting symptoms included
tachycardia,
lethargy, and vague gastrointestinal distress. Patient fully recovered after supportive medical care and
clozapine discontinuation. Conclusions.
Myocarditis is a known potential complication of
clozapine initiation; however, due to its limited usage in the pediatric population, reported cases are limited. There is a need to establish evidence-based monitoring guidelines for
clozapine usage, particularly in the pediatric population where the presentation may be atypical and clinical suspicion may be overlooked.